TY - JOUR
T1 - Type i NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma
AU - Renukaradhya, Gourapura J.
AU - Khan, Masood A.
AU - Vieira, Marcus
AU - Du, Wenjun
AU - Gervay-Hague, Jacquelyn
AU - Brutkiewicz, Randy R.
PY - 2008/6/15
Y1 - 2008/6/15
N2 - Natural killer T (NKT) cells are a T-cell subpopulation known to possess immu-noregulatory functions and recognize CD1d molecules. The majority of NKT cells express an invariant T-cell receptor (TCR) α chain rearrangement (Vα14Jα18 in mice; Vα24Jα18 in humans) and are called type I NKT cells; all other NKT cells are type II. In the current study, we have analyzed the roles for these NKT-cell subsets in the host's innate antitumor response against a murine B-cell lym-phoma model in vivo. In tumor-bearing mice, we found that type I NKT cells conferred protection in a CD1d- dependent manner, whereas type II NKT cells exhibited inhibitory activity. Pro- and anti-inflammatory cytokines secreted by splenocytes from tumor-bearing mice correlated with tumor progression. Myeloid cells (CD11b+Gr1 +) were present in large numbers at the tumor site and in the spleen of tumor-bearing type I NKT-deficient mice, suggesting that antitumor immunosurveillance was inhibited by CD11b+Gr1+ cells. Overall, these data suggest that there are distinct roles for NKT-cell subsets in response to a B-cell lymphoma in vivo, pointing to potential novel targets to be exploited in immuno-therapeutic approaches against blood cancers.
AB - Natural killer T (NKT) cells are a T-cell subpopulation known to possess immu-noregulatory functions and recognize CD1d molecules. The majority of NKT cells express an invariant T-cell receptor (TCR) α chain rearrangement (Vα14Jα18 in mice; Vα24Jα18 in humans) and are called type I NKT cells; all other NKT cells are type II. In the current study, we have analyzed the roles for these NKT-cell subsets in the host's innate antitumor response against a murine B-cell lym-phoma model in vivo. In tumor-bearing mice, we found that type I NKT cells conferred protection in a CD1d- dependent manner, whereas type II NKT cells exhibited inhibitory activity. Pro- and anti-inflammatory cytokines secreted by splenocytes from tumor-bearing mice correlated with tumor progression. Myeloid cells (CD11b+Gr1 +) were present in large numbers at the tumor site and in the spleen of tumor-bearing type I NKT-deficient mice, suggesting that antitumor immunosurveillance was inhibited by CD11b+Gr1+ cells. Overall, these data suggest that there are distinct roles for NKT-cell subsets in response to a B-cell lymphoma in vivo, pointing to potential novel targets to be exploited in immuno-therapeutic approaches against blood cancers.
UR - http://www.scopus.com/inward/record.url?scp=47049090132&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-05-092866
DO - 10.1182/blood-2007-05-092866
M3 - Article
C2 - 18417738
AN - SCOPUS:47049090132
SN - 0006-4971
VL - 111
SP - 5637
EP - 5645
JO - Blood
JF - Blood
IS - 12
ER -